Literature DB >> 4054527

Surveillance for colonic carcinoma in ulcerative colitis.

E Rosenstock, R G Farmer, R Petras, M V Sivak, G B Rankin, B H Sullivan.   

Abstract

To evaluate the efficacy of surveillance colonoscopy with biopsy for the detection of high-grade dysplasia (HGD) or colonic carcinoma in patients with chronic ulcerative colitis, we undertook a retrospective review of 248 patients who underwent 370 examinations (mean duration of disease 12 yr). High-grade dysplasia or carcinoma was found in 24 examinations in 16 patients, with a mean duration of disease of 16 yr. There were 15 patients with HGD. Nine patients had HGD alone, 6 had HGD and carcinoma, and 1 had carcinoma without HGD. The overall incidence of HGD was 6%. Dysplasia-associated lesions or mass were the most consistent indicators of carcinoma, the combination being present in four instances. Of the 7 patients with cancer, 6 were recognized by colonoscopy, and 1 patient with negative visual endoscopic findings was discovered using surveillance biopsies. The conclusions of this study are that dysplasia is a reliable histopathologic marker and correlates with the presence of cancer in chronic ulcerative colitis; the absence of dysplasia correlates with the absence of cancer. The presence of dysplasia-associated lesions or mass with HGD is the strongest indication for operation. This study supports the use of surveillance colonoscopy in managing high-risk ulcerative colitis patients.

Entities:  

Mesh:

Year:  1985        PMID: 4054527     DOI: 10.1016/0016-5085(85)90653-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  41 in total

Review 1.  Screening for colorectal cancer in ulcerative colitis: dubious benefits and high costs.

Authors:  S Gyde
Journal:  Gut       Date:  1990-10       Impact factor: 23.059

2.  The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice.

Authors:  Yugo Ando; Guo-Xiang Yang; Masanobu Tsuda; Kazuhito Kawata; Weici Zhang; Takahiko Nakajima; Koichi Tsuneyama; Patrick Leung; Zhe-Xiong Lian; Kazuichi Okazaki; William M Ridgway; Gary L Norman; Aftab A Ansari; Xiao-Song He; Ross L Coppel; M Eric Gershwin
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

Review 3.  Inflammatory bowel disease: the problems of dysplasia and surveillance.

Authors:  P J Mitchell; E Salmo; N Y Haboubi
Journal:  Tech Coloproctol       Date:  2007-11-30       Impact factor: 3.781

Review 4.  Screening for gastrointestinal cancer: an epidemiological review.

Authors:  J Weil; M J Langman
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

Review 5.  How do we assess the value of surveillance techniques in ulcerative colitis?

Authors:  C N Bernstein
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

Review 6.  Biology of colorectal cancer in ulcerative colitis.

Authors:  B A Lashner; B D Shapiro
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

7.  Patients with Endoscopically Visible Polypoid Adenomatous Lesions Within the Extent of Ulcerative Colitis Have an Increased Risk of Colorectal Cancer Despite Endoscopic Resection.

Authors:  Venkataraman Subramanian; Sukhdev Chatu; Fabian Echterdiek; Ashwini Banerjee; Caroline Finlayson; Richard C G Pollok
Journal:  Dig Dis Sci       Date:  2016-07-12       Impact factor: 3.199

8.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 9.  Failure of colonoscopic surveillance in ulcerative colitis.

Authors:  D A Lynch; A J Lobo; G M Sobala; M F Dixon; A T Axon
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

10.  Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease.

Authors:  M W M D Lutgens; B Oldenburg; P D Siersema; A A van Bodegraven; G Dijkstra; D W Hommes; D J de Jong; P C F Stokkers; C J van der Woude; F P Vleggaar
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.